Solid Tumor Cancer Plasma

About Solid Tumor Cancer Plasma

Solid Tumor Cancer Plasma for Liquid Biopsy and Tumour Immunology Research

Solid Tumor Cancer Plasma is collected from IRB-consented donors with clinically confirmed solid tumour malignancies and processed within one day of collection to preserve cell-free nucleic acids, cytokines, proteins and metabolites. Solid tumours are neoplastic diseases, and plasma is the single most important specimen in modern liquid biopsy: it is the compartment where circulating tumour DNA, cell-free RNA and tumour-derived vesicles are found, and where soluble immune mediators reflecting the tumour-host interaction are measured.

Why Plasma for Solid Tumour Cancer

The distinction between serum and plasma is not cosmetic in oncology. Clot formation causes leukocyte lysis that floods the sample with genomic DNA from white cells, diluting the tumour-derived fraction. Anticoagulated, promptly processed plasma is the accepted matrix for cell-free DNA work for exactly this reason.

• Circulating tumour DNA — tumour-derived fragments make up a variable and often very small fraction of total cell-free DNA. Preserving that fraction depends on the preanalytical variables this product controls: anticoagulant choice, prompt processing and controlled time to freeze.
• Tumour fraction scales with burden — ctDNA levels generally track disease burden, which is why plasma underpins research into minimal residual disease detection, treatment response monitoring and early relapse identification.
• Resistance mutation tracking — plasma allows emergence of resistance alterations under targeted therapy to be studied longitudinally without repeat tissue biopsy, which is often not feasible.
• Methylation and fragmentomics — tissue-of-origin inference from cell-free DNA methylation patterns and fragment-length profiles is a major current direction in multi-cancer early detection, and both require intact, high-quality plasma cfDNA.
• Extracellular vesicles and cell-free RNA — tumour-derived vesicle and cfRNA analysis is compromised in serum by platelet-derived contamination, making plasma the correct choice.
• Soluble immune mediators — cytokines, chemokines and soluble checkpoint proteins measured in plasma support research into checkpoint inhibitor response and immune-related toxicity, alongside the genomic readouts from the same aliquot.

Donor Stratification Available

• Primary tumour type and site, with pan-tumour or single-indication cohorts assembled to request
• Disease extent: localised, locally advanced, or metastatic; stage where recorded
• Treatment status and line of therapy: treatment-naive, chemotherapy, targeted therapy, checkpoint inhibitor, or post-resection
• Molecular and biomarker status where reported in the clinical record, including driver alterations and PD-L1
• Response status and progression events where documented
• Serial or longitudinal collections from the same donor where available
• Matched healthy controls available, age- and sex-matched and processed under identical SOPs

Product Features

• Research Use Only (RUO)
• Plasma collected from clinically confirmed solid tumour cancer donors
• Processed within one day of collection with controlled time to freeze
• Anticoagulant of choice available on request, including EDTA and cell-free DNA preservation tubes
• Double-spin processing available for cell-free nucleic acid applications
• IRB-approved protocols and informed consent
• Custom aliquot volumes available upon request; volumes reported per lot

De-identified Donor Data

• Verified solid tumour cancer diagnosis with primary site and histology where available
• Demographic data: age, sex assigned at birth, race/ethnicity
• Donor-reported medications, allergies and comorbidities
• Stage, molecular status and treatment history where reported
• Additional solid tumour cancer-specific metadata available on request

Applications

• Circulating tumour DNA detection, quantification and sequencing panel development
• Minimal residual disease and treatment response monitoring research
• Resistance mutation emergence and longitudinal tracking studies
• Cell-free DNA methylation and fragmentomics for multi-cancer early detection
• Extracellular vesicle and cell-free RNA isolation and characterisation
• Cytokine, chemokine and soluble checkpoint protein profiling
• Plasma proteomics, metabolomics and multiplex panel development
• Preanalytical variable and assay validation studies for liquid biopsy platforms

Other Solid Tumor Cancer Specimen Types

• Solid Tumor Cancer Serum
• Solid Tumor Cancer Whole Blood — for circulating tumour cell work
• Solid Tumor Cancer PBMC
• Solid Tumor Cancer Leukopak

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Solid Tumor Cancer plasma is available in standard and custom volumes. For pricing, availability or a specific tumour-type or longitudinal cohort request, email learnmore@sanguinebio.com; please also contact us for international orders or documentation requirements to ensure compatibility with your country’s regulations. To browse availability across all disease states, visit our human plasma page.